Oswald Bostic
Southfield, MINPI 1063439586
Payments from drug & device makers
$2,772in general payments, 2019–2025
Across 176 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$684
- AstraZeneca$307
- Amgen$286
- Johnson & Johnson$235
- Boehringer Ingelheim$217
- Merck$206
- plus $838 from 13 others
What the payments were for
- Food & beverage$2,69997%
- Education$100%
- Other$642%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
19
20
21
22
23
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 44 | $684 |
| AstraZeneca | 21 | $307 |
| Amgen | 17 | $286 |
| Johnson & Johnson | 15 | $235 |
| Boehringer Ingelheim | 14 | $217 |
| Merck | 14 | $206 |
| Arbor Pharmaceuticals, Inc. | 14 | $193 |
| E.r. Squibb & Sons, L.L.C. | 10 | $146 |
| Pfizer | 10 | $145 |
| Bayer | 5 | $91 |
| Baxter Healthcare | 1 | $64 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Edwards Lifesciences | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| CMP Pharma, Inc. | 1 | $16 |
| Boston Scientific | 1 | $13 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 18 | $150 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.